Arrowhead Pharmaceuticals (ARWR) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Arrowhead Pharmaceuticals (NASDAQ: ARWR):

  • 11/17/2026 – Arrowhead Pharmaceuticals had its price target lowered by Citigroup from $108.00 to $105.00. They now have a “buy” rating on the stock.
  • 11/14/2026 – Arrowhead Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “strong sell”.
  • 11/13/2026 – Arrowhead Pharmaceuticals had its “sell (d-)” rating reaffirmed by Weiss Ratings.
  • 11/13/2026 – Arrowhead Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $100.00 price target on the stock.
  • 11/13/2026 – Arrowhead Pharmaceuticals had its price target lowered by Stifel Nicolaus from $104.00 to $96.00. They now have a “buy” rating on the stock.
  • 10/15/2026 – Arrowhead Pharmaceuticals is now covered by UBS Group. They set a “buy” rating and a $109.00 price target on the stock.
  • 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $115.00 price target on the stock.
  • 10/15/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $120.00 price target on the stock.
  • 10/14/2026 – Arrowhead Pharmaceuticals was upgraded by UBS Group to “strong-buy”.
  • 9/24/2026 – Arrowhead Pharmaceuticals is now covered by The Goldman Sachs Group. They set a “neutral” rating and a $74.00 price target on the stock.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ:ARWR traded up $0.12 during trading hours on Wednesday, reaching $43.11. The stock had a trading volume of 2,421,466 shares, compared to its average volume of 2,076,011. The company has a debt-to-equity ratio of 16.61, a quick ratio of 4.11 and a current ratio of 4.14. The stock has a 50 day simple moving average of $60.85 and a 200 day simple moving average of $70.63. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $37.06 and a 12-month high of $95.49. The stock has a market cap of $6.09 billion, a P/E ratio of -8.44 and a beta of 1.34.

Arrowhead Pharmaceuticals is a biotechnology company that develops medicines using RNA interference (RNAi), a biological process that can reduce the production of specific proteins by silencing the genes that encode them. Its proprietary Targeted RNAi Molecule (TRiM) platform is designed to deliver RNAi treatments to targeted tissues. The company’s research and development programs address a range of conditions, including liver, cardiometabolic, pulmonary and neurological diseases. Its work centers on investigational medicines and drug-development partnerships.

Read More

Receive News & Ratings for Arrowhead Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.